PDS Biotechnology Reports Financial Results for Third Quarter
PDS Biotechnology Corporation (NASDAQ: PDSB) recently shared its financial results for the quarter ending on September 30, 2025. The company, based in Princeton, N.J., is at the forefront of innovation, focusing on immunotherapy to combat cancer.
Clinical Trial Updates
PDS Biotech announced significant developments in its clinical programs, particularly the completion of the VERSATILE-002 Phase 2 trial. This trial explored the combination of PDS0101 and Pembrolizumab for treating patients with HPV16-positive recurrent/metastatic head and neck cancer.
Positive Outcomes from VERSATILE-002
The results from VERSATILE-002 demonstrated promising data, showing a median overall survival (mOS) of 39.3 months for patients with a combined positive score (CPS) of 1 or higher. As a result, the company is now seeking an expedited approval pathway for its subsequent VERSATILE-003 Phase 3 trial.
Ongoing VERSATILE-003 Trial Plans
The ongoing Phase 3 trial, VERSATILE-003, is designed to compare PDS0101 in combination with Pembrolizumab against Pembrolizumab alone. Analysts believe that the promising progression-free survival (PFS) results could allow the clinical study’s duration to be shortened, expediting the path to regulatory submission.
Financial Overview for Q3 2025
For the third quarter, PDS Biotech reported a net loss of $9 million, or $0.19 per share, a decrease from the $10.7 million loss incurred during the same quarter last year. This reduction in net loss can be attributed to lower operating expenses, signaling strong financial management amid their extensive research initiatives.
Research and Development Expenses
Research and development expenses totaled $4.6 million for the quarter, down from $6.8 million the previous year. This decline reflects decreased manufacturing and clinical costs, which is a positive sign for the company's expenditure efficiency.
General and Administrative Costs
General and administrative expenses saw a slight rise to $3.6 million, up from $3.4 million the year prior, primarily due to increased professional fees. However, this increase was offset in part by reduced personnel costs, demonstrating the company’s focus on maintaining financial health.
Significant Cash Position
As of September 30, 2025, PDS Biotech held a cash balance of $26.2 million, significantly down from $41.7 million at the end of the prior year. The company executed a strategic move to bolster its capital, having sold 5.8 million shares along with accompanying warrants, raising approximately $5.3 million.
Upcoming Conference Call
On November 13, 2025, PDS Biotech will hold a conference call at 8:00 a.m. Eastern Time to discuss these developments in detail with stakeholders and analysts. This event provides an opportunity to delve deeper into the implications of their latest data and future plans.
About PDS Biotechnology
PDS Biotech is dedicated to transforming the way the immune system confronts cancer. Their lead investigational immunotherapy, PDS0101, aims to harness the body’s immune response, offering hope to patients battling various cancers. With a focus on research, development, and clinical trials, PDS Biotech is pioneering new pathways in cancer treatment.
Frequently Asked Questions
What were PDS Biotech's financial results for Q3 2025?
PDS Biotech reported a net loss of $9 million, or $0.19 per share, for Q3 2025.
What was the purpose of the VERSATILE-002 trial?
The VERSATILE-002 trial evaluated the effectiveness of PDS0101 combined with Pembrolizumab for treating HPV16-positive head and neck cancer.
How has PDS Biotech's cash position changed?
PDS Biotech's cash balance as of September 30, 2025, was $26.2 million, down from $41.7 million at the end of the previous year.
What are the next steps for PDS Biotech following the VERSATILE-002 results?
The company plans to pursue an expedited approval pathway in the ongoing VERSATILE-003 Phase 3 trial.
What is PDS Biotech's main focus?
PDS Biotech focuses on developing immunotherapy treatments to enhance the immune system's ability to target and destroy cancer cells.
